SPLENECTOMY AND SEPSIS: THE ROLE OF THE SPLEEN IN THE IMMUNE-MEDIATED BACTERIAL CLEARANCE

REFERENCES

• O'Neal B. J., McDonald J. C. The risk of sepsis in the asplenic adult. Ann. Surg. 1981; 194: 775
   PubMed Web of Science ®Google Scholar
• Brigden M. L. Overwhelming postsplenectomy infection still a problem. West. J. Med. 1992; 157: 440
   PubMedGoogle Scholar
• Norris R. P., Vergis E. N., Yu V. L. Overwhelming postsplenectomy infection: a critical review of etiologic pathogens and management. Infect. Med. 1996; 13: 779
   Google Scholar
• Goud S. N., Muthusamy N., Subbarao B. Differential responses of B cells from the spleen and lymph node to TNP-Ficoll. J. Immunol. 1988; 140: 2925
   PubMedGoogle Scholar
• van den Dobbelsteen G. P.J.M., Brunekreef K., Kroes H., et al. Enhanced triggering of mucosal immune responses by reducing splenic phagocytic functions. Eur. J. Immunol. 1993; 23: 1448
   Google Scholar
• Hebert J. C., O' Reilly M., Yuenger K., et al. Augmentation of alveolar macrophage phagocytic activity by granulocyte colony stimulating factor and interleukin-1: influence of splenectomy. J. Trauma 1994; 37: 909
   PubMed Web of Science ®Google Scholar
• Freudenberg N., Freudenberg M. A., Bandara K., et al. Distribution and localization of endotoxin in the reticulo-endothelial system (RES) and in the main vessels of the rat during shock. Pathol. Res. Pract. 1985; 179: 517
   PubMedGoogle Scholar
• Moeniralam H. S., Bemelman W. A., Enderte E., et al. The decrease in nonsplenic interleukin-6 (IL-6) production after splenectomy indicates the existence of a positive feedback loop of IL-6 production during endotoxemia in dogs. Infect. Immun. 1997; 65: 2299
   PubMedGoogle Scholar
• Timens W. The human spleen and the immune system: not just another lymphoid organ. Res. Immunol. 1991; 142: 316
   PubMedGoogle Scholar
• Adkins B., Bu Y., Cepero E., et al. Exclusive Th2 primary effector function in spleens but mixed Th1/Th2 function in lymph nodes of murine neonates. J. Immunol. 2000; 164: 2347
   PubMedGoogle Scholar
• Görgen I., Hartung T., Leist M., et al. Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-α. J. Immunol. 1992; 149: 918
   PubMed Web of Science ®Google Scholar
• Miniello S., Jirillo E., Urgesi G. Immunodepressione dopo splenectomia per rottura traumatica. Atti XXV Congresso Nazionale Società, G. M. Bonomo, F. Falcone. Italiana Chirurgia Urgenza. 1997; 235
   Google Scholar
• Jirillo E., Antonaci S. Interactions of lymphocytes with bacterial antigens. Diagn. Clin. Immunol. 1988; 5: 279
   PubMedGoogle Scholar
• Jirillo E., Antonaci S. Spontaneous adherence of Salmonella typhosa to human peripheral blood lymphocytes in typhoid fever. Infection 1985; 13: 157
   PubMedGoogle Scholar
• Miniello S., Jirillo E., Urgesi G., et al. Studio delle citochine Th1–Th2 correlate (IFN-γ e IL-4) negli splenectomizzati. Chir. Ital. 1999; 51: 215
   PubMedGoogle Scholar
• Mori M., Morris S. C., Orekhova T., et al. IL-4 promotes the migration of circulating B cells to the spleen and increases splenic B cell survival. J. Immunol. 2000; 164: 5704
   PubMedGoogle Scholar
• Kühn R., Rajewsky K., Müller W. Generation and analysis of interleukin-4 deficient mice. Science 1991; 254: 707
   PubMed Web of Science ®Google Scholar
• Erb K. J., Ruger B., von Brevern M., et al. Constitutive expression of interleukin (IL)-4 in vivo causes autoimmune-type disorders in mice. J. Exp. Med. 1997; 185: 329
   PubMedGoogle Scholar
• Pugin J., Heumann I. D., Tomasz A., et al. CD14 is a pattern recognition receptor. Immunity 1994; 1: 509
   PubMed Web of Science ®Google Scholar
• Espevik T., Otterlei M., Skjak-Braek G., et al. The involvement of CD14 in stimulation of cytokine production by uronic acid polymers. Eur. J. Immunol. 1993; 23: 255
   PubMed Web of Science ®Google Scholar
• Medvedev A. E., Flo T., Ingalls R. R., et al. Involvement of CD14 and complement receptors CR3 and CR4 in nuclear factor-kappa B activation and TNF production induced by lipopolysaccharide and group B streptococcal cell walls. J. Immunol. 1998; 160: 4535
   PubMed Web of Science ®Google Scholar
• Jirillo E. (guest editor), Immunomodulation by the lipid A entity of bacterial lipopolysaccharides. Int. Rev. Immunol. 1990; 6: 207
   PubMedGoogle Scholar
• Hailman E., Lichenstein H. S., Wurfel M. M., et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J. Exp. Med. 1994; 179: 269
   PubMed Web of Science ®Google Scholar
• Ulevitch R. J., Tobias P. S. Recognition of endotoxin by cells leading to transmembrane signaling. Curr. Opin. Immunol. 1994; 6: 125
   PubMed Web of Science ®Google Scholar
• Yang R. B., Mark M. R., Gurney A. L., et al. Signaling events induced by lipopolysaccharide-activated toll-like receptor2. J. Immunol. 1999; 163: 639
   PubMed Web of Science ®Google Scholar
• MacFarlane A. S., Schwacha M. G., Eisenstein T. K. In vivo blockage of nitric oxide with aminoguanidine inhibits immunosuppression induced by an attenuated strain of Salmonella typhimurium, potentiates Salmonella infection, and inhibits macrophage and polymorphonuclear leukocyte influx into the spleen. Infect. Immun. 1999; 67: 891
   PubMed Web of Science ®Google Scholar
• Pugin J., Schürer M. C., Leturcq D., et al. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipolysaccharide-binding protein and soluble CD14. Proc. Natl. Acad. Sci. USA 1993; 90: 2744
   PubMed Web of Science ®Google Scholar
• Pece S., Giuliani G., Caccavo D., et al. The pathogenesis of fever and its therapeutic implications. Med. Sci. Res. 1998; 26: 3
   Google Scholar
• Dinarello C. A. Blocking interleukin-1 in sepsis. J. Endotoxin Res. 1995; 2: 157
   Google Scholar
• Malstrom C., James S. Inhibition of murine splenic and mucosal lymphocyte function by enteric bacterial products. Infect. Immun. 1998; 66: 3120
   PubMedGoogle Scholar
• Gibson F. C., III, Onderdonk A. B., Kasper D. L., et al. Cellular mechanism of intraabdominal abscess formation by Bacteroides fragilis. J. Immunol. 1998; 160: 5000
   PubMedGoogle Scholar
• Opal S. M., Horn D. L., Palardy J. E., et al. The in vivo significance of antibioticinduced endotoxin release in experimental gram-negative sepsis. J. Endotoxin Res. 1996; 3: 245
   Google Scholar
• Hirschmann J. V. Use of the pneumococcal polysaccharide vaccine is unwarranted in the U.S. ASM News 2000; 66: 326
   Google Scholar
• Andersson U. G., Björk L., Skansén-Saphir V., et al. Downregulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993; 79: 211
   PubMed Web of Science ®Google Scholar
• Reimund J. M., Dumont S., Muller C. D., et al. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 1997; 40: 475
   PubMed Web of Science ®Google Scholar
• Famularo G., De Simone C., Arrigoni Martelli E., et al. Carnitine and septic shock: a review. J. Endotoxin Res. 1995; 2: 141
   Google Scholar
• Targan S. R., Hanauer S. B., van Deventer S. J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor–alpha for Crohn's disease. Crohn'n disease cA2 study group. N. Engl. J. Med. 1997; 337: 1029
   PubMed Web of Science ®Google Scholar
• Stack W. A., Mann S. D., Roy A. J., et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997; 349: 521
   PubMed Web of Science ®Google Scholar
• Jirillo E., Amati L., Caradonna L., et al. Soluble (s) CD14 and plasmatic lipopolysaccharides (LPS) in patients with chronic hepatitis C before and after treatment with interferon (IFN)-alpha. Immunopharmacol. Immunotoxicol. 1998; 20: 1
   PubMed Web of Science ®Google Scholar
• Caradonna L., Amati L., Lella P., et al. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease. Am. J. Gastroenterol. 2000; 95: 1495
   PubMed Web of Science ®Google Scholar
• Amati L., Caradonna L., Greco B., et al. Impairment of phagocytic and T-cellmediated antibacterial activity and plasma endotoxins in patients with untreated gastrointestinal cancer. Scand. J. Gastroenterol. 1998; 33: 847
   PubMedGoogle Scholar